Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease

Nephrology Dialysis Transplantation

Volumn 30, Issue 11, 2015, Pages 1814-1824

  Gajjala, Prathibha R ^a   Fliser, Danilo ^b   Speer, Thimoteus ^b   Jankowski, Vera ^a   Jankowski, Joachim ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Carbamylation; Cardiovascular disease; Chronic kidney disease; Oxidation; Post translational modification

Indexed keywords

ADVANCED GLYCATION END PRODUCT; PROTEIN;

ATHEROSCLEROSIS; CARBAMOYLATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; REVIEW; CARDIOVASCULAR DISEASES; METABOLISM; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC;

CARDIOVASCULAR DISEASES; HUMANS; MASS SPECTROMETRY; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84935064641     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv048     Document Type: Review

References (99)

1. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 41(5 Suppl): 11-17
2. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol 2003; 21: 255-261
3. Gillery P, Jaisson S. Usefulness of non-enzymatic post-translational modification derived products (PTMDPs) as biomarkers of chronic diseases. J Proteomics 2013; 92: 228-238
4. Gillery P, Jaisson S. Post-translational modification derived products (PTMDPs): toxins in chronic diseases? Clin Chem Lab Med 2014; 52: 33-38
5. Schütz F. Cyanate. Experientia 1949; 5: 133-172
6. Stark GR SW, Moore S. Reaction of the cyanate present in aqueous urea with amino acids and proteins. J Biol Chem 1960; 235: 3177-3181
7. Kraus LM, Kraus AP, Jr. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001; 78: S102-S107
8. Jaisson S, Pietrement C, Gillery P. Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clin Chem 2011; 57: 1499-1505
9. Wang Z, Nicholls SJ, Rodriguez ER et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007; 13: 1176-1184
10. Isom DG, Castaneda CA, Cannon BR et al. Large shifts in pKa values of lysine residues buried inside a protein. Proc Natl Acad Sci USA 2011; 108: 5260-5265
11. Balion CM, Draisey TF, Thibert RJ. Carbamylated hemoglobin and carbamylated plasma protein in hemodialyzed patients. Kidney Int 1998; 53: 488-495
12. Jaisson S, Lorimier S, Ricard-Blum S et al. Impact of carbamylation on type I collagen conformational structure and its ability to activate human polymorphonuclear neutrophils. Chem Biol 2006; 13: 149-159
13. Jaisson S, Larreta-Garde V, Bellon G et al. Carbamylation differentially alters type I collagen sensitivity to various collagenases. Matrix Biol 2007; 26: 190-196
14. Jaisson S, Delevallee-Forte C, Toure F et al. Carbamylated albumin is a potent inhibitor of polymorphonuclear neutrophil respiratory burst. FEBS Lett 2007; 581: 1509-1513
15. Schreier SM, Steinkellner H, Jirovetz L et al. S-carbamoylation impairs the oxidant scavenging activity of cysteine: its possible impact on increased LDL modification in uraemia. Biochimie 2011; 93: 772-777
16. Samhan-Arias AK, Garcia-Bereguiain MA, Gutierrez-Merino C. Hydrogen sulfide is a reversible inhibitor of the NADH oxidase activity of synaptic plasma membranes. Biochem Biophys Res Commun 2009; 388: 718-722
17. Praschberger M, Hermann M, Laggner C et al. Carbamoylation abrogates the antioxidant potential of hydrogen sulfide. Biochimie 2013; 95: 2069-2075
18. Jin K. Effects of amino acids and albumin on erythropoietin carbamoylation. Clin Exp Nephrol 2013; 17: 575-581
19. Koeth RA, Kalantar-Zadeh K, Wang Z et al. Protein carbamylation predicts mortality in ESRD. J Am Soc Nephrol 2013; 24: 853-861
20. Holzer M, Zangger K, El-Gamal D et al. Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional highdensity lipoprotein. Antioxid Redox Signal 2012; 17: 1043-1052
21. Ok E, Basnakian AG, Apostolov EO et al. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int 2005; 68: 173-178
22. Apostolov EO, Ray D, Savenka AV et al. Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol 2010; 21: 1852-1857
23. Apostolov EO, Shah SV, Ray D et al. Scavenger receptors of endothelial cells mediate the uptake and cellular proatherogenic effects of carbamylated LDL. Arterioscler Thromb Vasc Biol 2009; 29: 1622-1630
24. Apostolov EO, Shah SV, Ok E et al. Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2007; 27: 826-832
25. Apostolov EO, Ray D, Alobuia WM et al. Endonuclease G mediates endothelial cell death induced by carbamylated LDL. Am J Physiol Heart Circ Physiol 2011; 300: H1997-H2004
26. Speer T, Owala FO, Holy EW et al. Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur Heart J 2014; 35: 3021-3032
27. Thornalley PJ, Rabbani N. Protein damage in diabetes and uremia - identifying hotspots of proteome damage where minimal modification is amplified to marked pathophysiological effect. Free Radic Res 2011; 45: 89-100
28. Sokolowska M, Lorenc-Koci E, Bilska A et al. The effect of lipoic acid on cyanate toxicity in different structures of the rat brain. Neurotox Res 2013; 24: 345-357
29. Simm A. Protein glycation during aging and in cardiovascular disease. J Proteomics 2013; 92: 248-259
30. Sell DR, Monnier VM. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 1990; 85: 380-384
31. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261: 4889-4894
32. Agalou S, Ahmed N, Babaei-Jadidi R et al. Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 2005; 16: 1471-1485
33. Maillard L-C. Action des acides amines sur les sucres: formation des melanoidines par voie methodique. C R Seances Acad Sci III 1912; 154: 66-68
34. Zhang Q, Ames JM, Smith RD et al. A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. J Proteome Res 2009; 8: 754-769
35. Thornalley PJ, Battah S, Ahmed N et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003; 375(Pt 3): 581-592
36. Rabbani N, Sebekova K, Sebekova K, Jr et al. Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. Kidney Int 2007; 72: 1113-1121
37. Sadik NA, Mohamed WA, Ahmed MI. The association of receptor of advanced glycated end products and inflammatory mediators contributes to endothelial dysfunction in a prospective study of acute kidney injury patients with sepsis. Mol Cell Biochem 2012; 359: 73-81
38. Tarng DC, Huang TP, Wei YH et al. 8-hydroxy-20-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. Am J Kidney Dis 2000; 36: 934-944
39. Selvaraj N, Bobby Z, Sridhar MG. Increased glycation of hemoglobin in chronic renal failure: [corrected] potential role of oxidative stress. Arch Med Res 2008; 39: 277-284
40. Meerwaldt R, Zeebregts CJ, Navis G et al. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am J Kidney Dis 2009; 53: 138-150
41. Wang AY, Wong CK, Yau YY et al. Skin autofluorescence associates with vascular calcification in chronic kidney disease. Arterioscler Thromb Vasc Biol 2014; 34: 1784-1790
42. Zieman S, Kass D. Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease. Congest Heart Fail 2004; 10: 144-149; quiz 150-141
43. Kumeda Y, Inaba M, Shoji S et al. Significant correlation of glycated albumin, but not glycated haemoglobin, with arterial stiffening in haemodialysis patients with type 2 diabetes. Clin Endocrinol (Oxf) 2008; 69: 556-561
44. Yamada S, Inaba M, Shidara K et al. Association of glycated albumin, but not glycated hemoglobin, with peripheral vascular calcification in hemodialysis patients with type 2 diabetes. Life Sci 2008; 83: 516-519
45. Ferretti G, Bacchetti T, Negre-Salvayre A et al. Structural modifications of HDL and functional consequences. Atherosclerosis 2006; 184: 1-7
46. Godfrey L, Yamada-Fowler N, Smith J et al. Arginine-directed glycation and decreased HDL plasma concentration and functionality. Nutr Diabetes 2014; 4: e134
47. Busch M, Franke S, Ruster C et al. Advanced glycation end-products and the kidney. Eur J Clin Invest 2010; 40: 742-755
48. Rebholz CM, Astor BC, Grams ME et al. Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. Nephrol Dial Transplant 2015; 30: 77-83
49. Hartog JW, Willemsen S, van Veldhuisen DJ et al. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail 2011; 13: 899-908
50. Thornalley PJ, Minhas HS. Rapid hydrolysis and slow alpha,beta-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein crosslinks. Biochem Pharmacol 1999; 57: 303-307
51. Zhang Y, Lapidos KA, Gal-Moscovici A et al. A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease. Artif Organs 2014; 38: 474-483
52. Xue M, Rabbani N, Momiji H et al. Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem J 2012; 443: 213-222
53. Xue M, Momiji H, Rabbani N et al. Frequency Modulated translocational oscillations of Nrf2 mediate the antioxidant response element cytoprotective transcriptional response. Antioxid Redox Signal 2015; 23: 613-629
54. Kerdelhue B, Tartar A, Lenoir V et al. Binding studies of substance P anterior pituitary binding sites: changes in substance P binding sites during the rat estrous cycle. Regul Pept 1985; 10: 133-143
55. Bierhaus A, Fleming T, Stoyanov S et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012; 18: 926-933
56. Grimsrud PA, Xie H, Griffin TJ et al. Oxidative stress and covalent modification of protein with bioactive aldehydes. J Biol Chem 2008; 283: 21837-21841
57. Shapiro HM. Redox balance in the body: an approach to quantitation. J Surg Res 1972; 13: 138-152
58. Fassett RG, Venuthurupalli SK, Gobe GC et al. Biomarkers in chronic kidney disease: a review. Kidney Int 2011; 80: 806-821
59. Vivekanandan-Giri A, Byun J, Pennathur S. Quantitative analysis of amino acid oxidation markers by tandem mass spectrometry. Methods Enzymol 2011; 491: 73-89
60. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313
61. Matsuyama Y, Terawaki H, Terada T et al. Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease. Clin Exp Nephrol 2009; 13: 308-315
62. Puchades Montesa MJ, Gonzalez Rico MA, Solis Salguero MA et al. [Study of oxidative stress in advanced kidney disease]. Nefrologia 2009; 29: 464-473
63. Caimi G, Carollo C, Hopps E et al. Protein oxidation in chronic kidney disease. Clin Hemorheol Microcirc 2013; 54: 409-413
64. Selmeci L. Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome? Free Radic Res 2011; 45: 1115-1123
65. Ruggiero C, Elks CM, Kruger C et al. Albumin-bound fatty acids but not albumin itself alter redox balance in tubular epithelial cells and induce a peroxide-mediated redox-sensitive apoptosis. Am J Physiol Renal Physiol 2014; 306: F896-F906
66. Mandal AK, Woodi M, Sood V et al. Quantitation and characterization of glutathionyl haemoglobin as an oxidative stress marker in chronic renal failure by mass spectrometry. Clin Biochem 2007; 40: 986-994
67. Piroddi M, Palmese A, Pilolli F et al. Plasma nitroproteome of kidney disease patients. Amino Acids 2011; 40: 653-667
68. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005; 45: 39-47
69. Tousoulis D, Kampoli AM, Tentolouris C et al. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 2012; 10: 4-18
70. Erwin PA, Mitchell DA, Sartoretto J et al. Subcellular targeting and differential S-nitrosylation of endothelial nitric-oxide synthase. J Biol Chem 2006; 281: 151-157
71. Donnini S, Monti M, Roncone R et al. Peroxynitrite inactivates humantissue inhibitor of metalloproteinase-4. FEBS Lett 2008; 582: 1135-1140
72. Cavigiolio G, Geier EG, Shao B et al. Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins. J Biol Chem 2010; 285: 18847-18857
73. Shao B, Tang C, Sinha A et al. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res 2014; 114: 1733-1742
74. Vaisar T, Mayer P, Nilsson E et al. HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin Chim Acta 2010; 411: 972-979
75. Sini S, Deepa D, Harikrishnan S et al. Evidence for an exclusive association of matrix metalloproteinase-9 with dysfunctional high-density lipoprotein: a novel finding. Atherosclerosis 2014; 236: 162-168
76. Huang Y, DiDonato JA, Levison BS et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 2014; 20: 193-203
77. Stephen EA, Venkatasubramaniam A, Good TA et al. The effect of oxidation on the mechanical response and microstructure of porcine aortas. J Biomed Mater Res A 2014; 102: 3255-3262
78. Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010; 298: F662-F671
79. Reisman SA, Chertow GM, Hebbar S et al. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. J Am Soc Nephrol 2012; 23: 1663-1673
80. Chin MP, Wrolstad D, Bakris GL et al. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail 2014; 20: 953-958
81. Hsu SP, Chiang CK, Yang SY et al. N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients. Nephron Clin Pract 2010; 116: c207-c216
82. Aluganti Narasimhulu C, Selvarajan K, Brown M et al. Cationic peptides neutralize Ox-LDL, prevent its uptake by macrophages, and attenuate inflammatory response. Atherosclerosis 2014; 236: 133-141
83. Rabbani N, Thornalley PJ. Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples. Nat Protoc 2014; 9: 1969-1979
84. Thornalley PJ, Rabbani N. Detection of oxidized and glycated proteins in clinical samples using mass spectrometry-a user's perspective. Biochim Biophys Acta 2014; 1840: 818-829
85. Apostolov EO, Shah SV, Ok E et al. Quantification of carbamylated LDL in human sera by a new sandwich ELISA. Clin Chem 2005; 51: 719-728
86. Heiene R, Vulliet PR, Williams RL et al. Use of capillary electrophoresis to quantitate carbamylated hemoglobin concentrations in dogs with renal failure. Am J Vet Res 2001; 62: 1302-1306
87. Jaisson S, Leroy N, Meurice J et al. First evaluation of Capillarys 2 Flex Piercing(R) (Sebia) as a new analyzer for HbA1c assay by capillary electrophoresis. Clin Chem Lab Med 2012; 50: 1769-1775
88. Kwan JT, Carr EC, Bending MR et al. Determination of carbamylated hemoglobin by high-performance liquid chromatography. Clin Chem 1990; 36: 607-610
89. Jaisson S, Gorisse L, Pietrement C et al. Quantification of plasma homocitrulline using hydrophilic interaction liquid chromatography (HILIC) coupled to tandem mass spectrometry. Anal Bioanal Chem 2012; 402: 1635-1641
90. Kume S, Takeya M, Mori T et al. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995; 147: 654-667
91. Munch G, Keis R, Wessels A et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997; 35: 669-677
92. Meerwaldt R, Hartog JW, Graaff R et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3687-3693
93. Frolov A, Hoffmann R. Identification and relative quantification of specific glycation sites in human serum albumin. Anal Bioanal Chem 2010; 397: 2349-2356
94. Hashimoto C, Iwaihara Y, Chen SJ et al. Highly-sensitive detection of free advanced glycation end-products by liquid chromatography-electrospray ionization-tandem mass spectrometry with 2,4,6-trinitrobenzene sulfonate derivatization. Anal Chem 2013; 85: 4289-4295
95. Tseng JY, Ghazaryan AA, Lo W et al. Multiphoton spectral microscopy for imaging and quantification of tissue glycation. Biomed Opt Express 2010; 2: 218-230
96. Mittelmaier S, Pischetsrieder M. Multistep ultrahigh performance liquid chromatography/tandem mass spectrometry analysis for untargeted quantification of glycating activity and identification of most relevant glycation products. Anal Chem 2011; 83: 9660-9668
97. Leeuwenburgh C, Rasmussen JE, Hsu FF et al. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 1997; 272: 3520-3526
98. Tyther R, Ahmeda A, Johns E et al. Protein carbonylation in kidney medulla of the spontaneously hypertensive rat. Proteomics Clin App 2009; 3: 338-346
99. Tyther R, Ahmeda A, Johns E et al. Proteomic identification of tyrosine nitration targets in kidney of spontaneously hypertensive rats. Proteomics 2007; 7: 4555-4564